T. Rowe Price Associates
SION

T. Rowe Price Associates’s Sionna Therapeutics SION Stock Holding History

T. Rowe Price Associates’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21M Sell
478,016
-278,360
-37% -$11.1M ﹤0.01% 1137
2026
Q1 		$30.3M Sell
756,376
-74,997
-9% -$2.86M ﹤0.01% 927
2025
Q4 		$34.2M Buy
831,373
+193,613
+30% +$7.34M ﹤0.01% 928
2025
Q3 		$18.8M Sell
637,760
-223,478
-26% -$4.86M ﹤0.01% 1070
2025
Q2 		$14.9M Sell
861,238
-134,974
-14% -$1.77M ﹤0.01% 1030
2025
Q1 		$10.4M Buy
+996,212
New +$16.3M ﹤0.01% 1111

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates's SION Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Sionna Therapeutics (SION) stake by 37% in Q2 2026, selling an estimated $11.1M and leaving 478,016 shares worth $21M. The position accounts for ﹤0.01% of the portfolio, ranked #1137.

T. Rowe Price Associates first reported a position in SION in Q1 2025 and has held it in 6 quarters since. The position peaked at $34.2M in Q4 2025. 146 funds tracked by Wall St. Rank hold SION as of Q2 2026.

  • T. Rowe Price Associates held 478,016 shares of Sionna Therapeutics worth $21M as of Q2 2026.
  • T. Rowe Price Associates sold 278,360 Sionna Therapeutics shares in Q2 2026, an estimated $11.1M.
  • Sionna Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1137 holding.
  • T. Rowe Price Associates first reported a position in Sionna Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • T. Rowe Price Associates's Sionna Therapeutics position peaked at $34.2M in Q4 2025.
  • 146 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.